PET is a non-invasive, translational imaging technology that quantitatively and safely measures the biology of disease.

The early renewal of their partnership reinforces each company’s commitment to increase the utilization of preclinical in vivo imaging and PET.

This new deal includes the expansion of technology development, including new proprietary detectors, as well as further scaling of manufacturing, efforts that position both companies for future growth.

Patrick Phelps, SOFIE’s President & CEO commented, "PerkinElmer and SOFIE see a unique market opportunity opened up by the departure of larger companies from the preclinical PET field.

"SOFIE has chosen to extend the partnership with our friends at PerkinElmer because of their world-class global service organization and relentless focus on the right imaging solutions to answer the biological questions of preclinical researchers."

This announcement comes at the start of the annual meeting of the Society of Nuclear Medicine & Molecular Imaging in San Diego, CA from June 11 – 15th.

SOFIE (Booth 936) and PerkinElmer (Booth 939) will showcase multimodal benchtop imaging systems with integrated animal handling for mice and rats and an automated radiochemical synthesis platform at the conference.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment.

The Company reported revenue of approximately $2.2 billion in 2014, has about 7,700 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.